Related Experiment Video

Updated: May 26, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras

David Matallanas1, David Romano, Fahd Al-Mulla

  • 1Systems Biology Ireland, University College Dublin, Dublin 4, Ireland.

Molecular Cell
|December 27, 2011
PubMed

Insights

Mutant K-Ras triggers apoptosis in colorectal cancer (CRC) by activating the MST2 pathway. However, wild-type K-Ras counteracts this effect, promoting tumor growth in CRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • K-Ras mutations are common in colorectal cancer (CRC).
  • K-Ras is the sole Ras isoform capable of inducing apoptosis.
  • Understanding K-Ras's role in CRC pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the mechanism by which mutant K-Ras induces apoptosis in CRC.
  • To investigate the interplay between mutant K-Ras, wild-type K-Ras, and apoptotic pathways.
  • To explore the clinical relevance of these molecular interactions in human CRC.

Main Methods:

  • Investigated direct binding of mutant K-Ras to RASSF1A.
  • Analyzed the activation of the MST2-LATS1-Mdm2-p53 apoptotic pathway.
  • Studied the role of autocrine EGF receptor (EGFR) activation and wild-type K-Ras in apoptosis.
  • Correlated K-Ras mutation status and MST2 expression in human CRC patients and mouse models.

Main Results:

  • Mutant K-Ras directly binds RASSF1A, activating the MST2-LATS1 pathway, leading to p53 stabilization and apoptosis.
  • Autocrine EGFR activation by mutant Ras counteracts apoptosis, a process dependent on wild-type K-Ras.
  • Wild-type K-Ras inhibits the MST2 pathway via AKT activation.
  • A negative correlation exists between K-Ras mutation and MST2 expression in CRC.
  • CRC tumors with co-expressed mutant K-Ras and MST2 exhibit higher apoptosis rates.

Conclusions:

  • In CRC, mutant K-Ras initiates apoptosis through the RASSF1A-MST2 pathway.
  • Wild-type K-Ras antagonizes mutant K-Ras-induced apoptosis, supporting tumor transformation.
  • Targeting the interplay between K-Ras alleles and apoptotic pathways may offer therapeutic strategies for CRC.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: